A panel of medical oncologists, nurse practitioners, and nurses specializing in breast, lung, and gastric cancers have a comprehensive discussion on antibody-drug conjugates, molecular testing, and best practices for treating patients.
EP. 1: Overview of Antibody-Drug Conjugates (ADCs)
A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).
EP. 2: Mechanisms of Action of Antibody-Drug Conjugates
The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.
EP. 3: Molecular Testing in Breast Cancer
A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.
EP. 4: Biomarker Testing in Gastrointestinal and Lung Cancers
Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.
EP. 5: Molecular Testing Considerations in Cancer Treatment
Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.
EP. 6: Best Practices for Patient Education Surrounding Cancer Treatment
The expert panel has a comprehensive discussion about best practices for patient education and the barriers to effective testing.
EP. 7: Antibody-Drug Conjugates in Breast Cancer
A breast medical oncologist provides insights on antibody-drug conjugates in the breast cancer space and discusses ongoing research.
EP. 8: Toxicity Management for T-DM1 and T-DXd in Breast Cancer
Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].
EP. 9: Antibody-Drug Conjugates in Lung Cancer
A medical oncologist reviews the antibody-drug conjugate landscape in lung cancer.
EP. 10: Management of ADC Toxicities in Lung Cancer
A nurse practitioner provides insights on toxicity management strategies for patients with lung cancer who are receiving antibody-drug conjugates.
EP. 11: Gastric Cancer Treatment: T-DXd
A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.
EP. 12: Managing T-DXd Toxicities in Gastric Cancer
Insights on managing antibody-drug conjugate toxicities for patients with gastric cancer.
EP. 13: Approved Antibody-Drug Conjugates in Breast, Lung, and GI Malignancies
A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.
EP. 14: TROP2-Targeting Antibody-Drug Conjugates
The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.
EP. 15: Treatment Considerations With TROP2-Targeted Therapy
Clinical insights on best practices for treating patients with TROP2-targeted therapy.
EP. 16: Future Directions in Gastric Cancer Treatment
Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.
EP. 17: Future Outlook for Treating Breast and Lung Cancers
Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.
EP. 18: Educating Community Specialists on Evolving Treatment Landscape
Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.
EP. 19: Closing Thoughts on Evolving Antibody-Drug Conjugate Landscape
The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.
Dr Phillips on the Treatment Landscape for Patients With MCL
Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
2 Commerce Drive Cranbury, NJ 08512